Loading
Pamela Kearns

Professor Pamela Kearns

Director, Institute of Cancer and Genomic Sciences, University of Birmingham

Prof. Pamela Kearns is Chair of Clinical Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham Women and Children’s Hospital. She is Director of the University of Birmingham’s Institute of Cancer and Genomic Sciences and Director of the Cancer Research UK Clinical Trials Unit (CRCTU). As Director of CRCTU, she leads the research strategy for one of the UK's largest cancer trials units, delivering a trials portfolio of over 100 multi-centre & international cancer trials for a wide range of cancers, occurring in all children, young people and adults, notably leading the National Children’s Cancer Trials Team responsible the vast majority of UK’s clinical trial portfolio for children and young people with cancer. Her research is focussed on research in childhood acute leukaemias and lymphomas and drug development and innovation in the design and delivery of clinical trials for childhood cancers.
She served as President of the European Society for Paediatric Oncology (SIOP Europe) from 2019 to 2021, having been a Board member since 2013 and now continues to sit on the Board of SIOP Europe as Past President. She has several European roles including Executive Board Member of the academic consortium ‘Innovative Therapeutics in Childhood Cancer’ (ITCC), Chair of ITCC’s European Sponsor Institutions Committee and Steering Committee member of the International multi- stakeholder platform ‘ACCELERATE’. Her research interests are focussed of drug development and innovation of design and delivery of clinical trials for childhood cancers. She was also a Senior Clinical Advisor to Cancer Research UK from 2015 to 2020 and is now as Trustee for Cancer Research UK as well as continuing to be a Trustee of a Child of Mine, a charity dedicated to supporting bereaved parents. She is also Chair of the Research Assessment Panel for GOSH Charity, and Chair of The Independent Scientific Advisory Panel for Bone Cancer Research Trust.

Sessions